Anti-tumor necrosis factor therapy in Crohn's disease: more information and more questions about the long term

Editorial

Charles N Bernstein. Clin Gastroenterol Hepatol. 2010 Jul.

. 2010 Jul;8(7):556-8.

doi: 10.1016/j.cgh.2010.04.014. Epub 2010 Apr 24.

No abstract available

Comment on

Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months.
Lichtenstein GR, Thomsen OØ, Schreiber S, Lawrance IC, Hanauer SB, Bloomfield R, Sandborn WJ; Precise 3 Study Investigators. Lichtenstein GR, et al. Clin Gastroenterol Hepatol. 2010 Jul;8(7):600-9. doi: 10.1016/j.cgh.2010.01.014. Epub 2010 Feb 1. Clin Gastroenterol Hepatol. 2010. PMID: 20117244 Clinical Trial.
Low-dose maintenance therapy with infliximab prevents postsurgical recurrence of Crohn's disease.
Sorrentino D, Paviotti A, Terrosu G, Avellini C, Geraci M, Zarifi D. Sorrentino D, et al. Clin Gastroenterol Hepatol. 2010 Jul;8(7):591-9.e1; quiz e78-9. doi: 10.1016/j.cgh.2010.01.016. Epub 2010 Feb 4. Clin Gastroenterol Hepatol. 2010. PMID: 20139033